United States securities and exchange commission logo





                             May 3, 2021

       David Southwell
       Chief Executive Officer
       TScan Therapeutics, Inc.
       830 Winter Street
       Waltham, MA 02451

                                                        Re: TScan Therapeutics,
Inc.
                                                            Amendment No. 1 to
Registration Statement on Form S-1
                                                            Filed April 30,
2021
                                                            File No. 333-255491

       Dear Mr. Southwell:

             We have reviewed your amended registration statement and have the
following
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.
Unless we note
       otherwise, our references to prior comments are to comments in our April
28, 2021 letter.

       Amendment No. 1 to Registration Statement on Form S-1 filed April 30,
2021

       Our Pipeline, page 2

   1.                                                   We note your response
to our prior comment 1. Please revise your disclosure to define the
                                                        abbreviations AML, ALL,
MDS and NSCLC when first used in your prospectus
                                                        summary.
       Our amended and restated certificate of incorporation provides that the
Court of Chancery...,
       page 89

   2.                                                   We note your response
to our prior comment 2. While your disclosure on pages 89 and
                                                        206 states that your
amended charter will provide that the exclusive forum provision will
                                                        not apply to claims
brought to enforce a duty or lability created by the Exchange Act, we
 David Southwell
TScan Therapeutics, Inc.
May 3, 2021
Page 2
      note that this is not clearly stated in the exclusive forum provision of
your amended
      charter to be effective upon the completion of this offering. Please
revise Section 12 of
      your Form of Amended and Restated Certificate of Incorporation to be
consistent with
      your disclosure in this section or provide reasonable assurance that you
will make future
      investors aware of the provision   s limited applicability (for example,
by including such
      disclosure in your future Exchange Act reports).
       You may contact Tara Harkins at 202-551-3639 or Angela Connell at
202-551-3426 if
you have questions regarding comments on the financial statements and related
matters. Please
contact Jane Park at 202-551-7439 or Tim Buchmiller at 202-551-3635 with any
other questions.



                                                           Sincerely,
FirstName LastNameDavid Southwell
                                                           Division of
Corporation Finance
Comapany NameTScan Therapeutics, Inc.
                                                           Office of Life
Sciences
May 3, 2021 Page 2
cc:       Timothy H. Ehrlich, Esq.
FirstName LastName